Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer

NCT: NCT06755359 · RECRUITING

NCT IDNCT06755359
StatusRECRUITING
Start Date2026-03-01
Completion2027-06
SponsorAlpha Tau Medical LTD. (INDUSTRY)
First posted
Last updated

Brief Summary

A unique approach for cancer treatment including radioactive sources named Alpha DaRT sources: Ra - 224 coated onto stainless steel tubes inserted into the tumor for the treatment of Locally Advanced Pancreatic Cancer .

Frequently Asked Questions

What is Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer?

Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer is a clinical trial registered under NCT06755359. Current status: RECRUITING.

What is the status of NCT06755359?

The current status of NCT06755359 (Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer) is: RECRUITING.

When did Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer start?

Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer started on 2026-03-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑